Drug Trial Radar · NCT00104260
Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin™ Treatment in Subjects With Phenylketonuria
Last checked: Nov 20, 2026Latest source record: Apr 9, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
700
Actual
Start
Dec 2004
Primary completion
Not stated
Study completion Nov 2005
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Feb 25, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the degree and frequency of response to Phenoptin™ (sapropterin dihydrochloride), as demonstrated by a reduction in blood phenylalanine (Phe) level among subjects with phenylketonuria (PKU) who have elevated Phe levels. A secondary objective of this study is to evaluate the safety of Phenoptin™ treatment in this subject population, and identify individuals in this subject population who respond to Phenoptin™ treatment with a reduction in blood Phe level.
Conditions
- Phenylketonurias
Interventions
sapropterin dihydrochlorideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the degree and frequency of response to Phenoptin™, as demonstrated by a reduction in blood Phe level among subjects with PKU who have elevated Phe levels
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Oakland, California
Site not named
New Haven, Connecticut
Site not named
Chicago, Illinois
Site not named
Boston, Massachusetts
Site not named
Minneapolis, Minnesota
Site not named
St Louis, Missouri
Site not named
New York, New York
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Dallas, Texas
Site not named
Salt Lake City, Utah
Site not named
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.